The SeriousTraders Newsletter If you are Serious about Trading, become a SeriousTrader!™

TransCode Therapeutics Inc. (NASDAQ: RNAZ)

Investment Considerations Lead candidate TTX-MC138 is advancing through a Phase I/II clinical trial for metastatic cancers, targeting the critical miR-10b biomarker. Proprietary TTX platform addresses a long-standing delivery bottleneck in RNA-based oncology drug development. Strategic collaborations with institutions like Massachusetts General Hospital and MD Anderson Cancer Center validate scientific rigor. Early human data demonstrates effective … Continue reading “TransCode Therapeutics Inc. (NASDAQ: RNAZ)”

View Profile